Dual antithrombotic therapy and gastroprotection in atrial fibrillation: an observational primary care study.
Charis Xuan XieJohn RobsonCrystal WilliamsChris CarvalhoStuart Christopher Gorthorn RisonZahra Raisi-EstabraghPublished in: BJGP open (2022)
Almost two-thirds of patients with AF on DAT were prescribed prolonged durations of therapy. Prescription of gastroprotection therapies was suboptimal in one in six patients. Treatment decisions varied by sex, age, ethnic group, and comorbidity. Duration of DAT and gastroprotection in patients with AF requires improvement.
Keyphrases
- atrial fibrillation
- primary care
- end stage renal disease
- oral anticoagulants
- newly diagnosed
- left atrial
- catheter ablation
- ejection fraction
- left atrial appendage
- heart failure
- chronic kidney disease
- stem cells
- percutaneous coronary intervention
- cross sectional
- patient reported outcomes
- replacement therapy
- coronary artery disease
- venous thromboembolism
- combination therapy
- smoking cessation
- left ventricular